Warning letters, 483s, Recalls, Import Alerts, Audit observations
The USFDA has issued a Warning Letter to Hyderabad-based OTC manufacturer Akron Formulations for critical
The Indian drug regulator, CDSCO, has published a list of spurious drugs detected in November
Adding to the growing number of drug recalls due to NDSRIs in 2024, Glenmark is
The USPTO is withdrawing the proposed new rule which was published in the Federal Register
USFDA has approved Checkpoint Therapeutics Cosibelimab-ipdl (Unloxcyt) for treatment of skin cancer CSCC (metastatic cutaneous squamous
The USFDA has approved Neurocrine Biosciences’ new drug, Crenessity (Crinecerfont), for the treatment of classic
Several lots of the antidepressant drug Duloxetine, manufactured by Aurobindo, India, have been recalled in
The Central Drugs Standard Control Organization (CDSCO) has issued a spurious drug alert for popular
In September 2024, the European Commission (EC) revoked the Conditional Marketing Authorisation (CMA) for Advanz
New Delhi based Unexo Life Sciences has initiated a major recall of several medicated patch
